Previous

Second schizophrenia treatment discovered at Vanderbilt’s Warren Center enters Phase I clinical trial
Next

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861